Fumihiro Kashizaki

Dr. Fumihiro Kashizaki

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2023 in Diseases
Verified
Journal Article
Open access
PDF file
KNKazunori Nakamura
Kazunori Nakamura
YFYukio Fujita
Yukio Fujita
HCHao Chen
Hao Chen
KSKohei Somekawa
Kohei Somekawa
FKFumihiro Kashizaki
Fumihiro Kashizaki
TKTakeshi Kaneko
Takeshi Kaneko
Background: Chronic obstructive pulmonary disease (COPD) is a prevalent condition with fewer treatments available as the severity increases. Previous systematic reviews have demonstrated the benefits of long-term macrolide use. However, the therapeutic differences between different macrolides and the optimal duration of use remain unclear. Methods: A systematic review and meta-analysis were conducted to assess the effectiveness of long-term macrolide use in reducing COPD exacerbations, compare the therapeutic differences among macrolides, and determine the appropriate treatment duration. Four databases (PubMed, Cochrane Library, Web of Science, and ICHU-SHI) were searched until 20 March 2023, and a random-effects model was used to calculate the pooled effect. Results: The meta-analysis included nine randomized controlled trials involving 1965 patients. The analysis revealed an odds ratio (OR) of 0.34 (95% confidence interval [CI] 0.19, 0.59, p < 0.001) for the reduction in exacerbation frequency. Notably, only azithromycin or erythromycin showed suppression of COPD exacerbations. The ORs for reducing exacerbation frequency per year and preventing hospitalizations were −0.50 (95% CI: −0.81, −0.19; p = 0.001) and 0.60 (95% CI: 0.3, 0.97; p = 0.04), respectively. Statistical analyses showed no significant differences between three- and six-month macrolide prescriptions. However, studies involving a twelve-month prescription showed an OR of 0.27 (95% CI: 0.11, 0.68; p = 0.005; I2 = 81%). Although a significant improvement in St George’s Respiratory Questionnaire (SGRQ) total scores was observed with a mean difference of −4.42 (95% CI: −9.0, 0.16; p = 0.06; I2 = 94%), the minimal clinically important difference was not reached. While no adverse effects were observed between the two groups, several studies have reported an increase in bacterial resistance. Conclusions: Long-term use of azithromycin or erythromycin suppresses COPD exacerbations, and previous studies have supported the advantages of a 12-month macrolide prescription over a placebo.

20 December 2024 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
FKFumihiro Kashizaki
Fumihiro Kashizaki
HCHao Chen
Hao Chen
NTNanami Tsuchiya
Nanami Tsuchiya
SMSachiko Matsumoto
Sachiko Matsumoto
ROReeko Osada
Reeko Osada
TKTakeshi Kaneko
Takeshi Kaneko

1 January 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
FKFumihiro Kashizaki
Fumihiro Kashizaki
ATArihito Tanaka
Arihito Tanaka
SHShigeaki Hattori
Shigeaki Hattori
SSShunsuke Sugimoto
Shunsuke Sugimoto

5 October 2023 in Clinical Lung Cancer
Verified
Journal Article
Closed access
FKFumihiro Kashizaki
Fumihiro Kashizaki
HCHao Chen
Hao Chen
AMAtsushi Miyasaka
Atsushi Miyasaka
NTNanami Tsuchiya
Nanami Tsuchiya
CYChihiro Yamada
Chihiro Yamada
TKTakeshi Kaneko
Takeshi Kaneko

24 August 2022 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
FKFumihiro Kashizaki
Fumihiro Kashizaki
ATArihito Tanaka
Arihito Tanaka
YSYasutomo Sekido
Yasutomo Sekido
Background: Anaplastic lymphoma kinase tyrosine kinase inhibitors are standard therapeutic agents prescribed for anaplastic lymphoma kinase-positive non-small cell lung cancer, and treatment with these agents has been shown to contribute to long-term survival in patients. However, there is no consensus regarding the course of treatment after the onset of anaplastic lymphoma kinase tyrosine kinase inhibitors related drug-induced interstitial lung disease. Here, we present a case of successful lorlatinib treatment after the onset of drug-induced interstitial lung disease caused by alectinib. Case presentation: A 57-year-old Japanese man was diagnosed with stage IVB non-small cell lung cancer by bronchoscopy, but gene mutation testing could not be performed because of the small amount of specimen. After diagnosis, first-line therapy with cisplatin/pemetrexed was initiated, but the patient developed renal dysfunction. Bronchoscopy was performed again to guide further treatment, and the non-small cell lung cancer was found to be anaplastic lymphoma kinase positive. Alectinib was started after the onset of progressive disease, but it resulted in drug-induced interstitial lung disease, necessitating alternative treatments. He subsequently received nanoparticle albumin bound paclitaxel, which was halted in view of the renal dysfunction. Thereafter, lorlatinib was administered, which was continued without drug-induced interstitial lung disease relapse. Conclusion: Since alectinib can occasionally cause drug-induced interstitial lung disease, as in the present case, lorlatinib may be an option to continue treatment in patients without other treatment alternatives.

10 January 2024 in Respiratory Investigation
Verified
Journal Article
Open access
YFYosuke Fukuda
Yosuke Fukuda
NHNobuyuki Horita
Nobuyuki Horita
MAMasaharu Aga
Masaharu Aga
FKFumihiro Kashizaki
Fumihiro Kashizaki
YHYu Hara
Yu Hara
HSHironori Sagara
Hironori Sagara
The evidence for macrolide therapy in adult asthma is not properly established and remains controversial. We conducted a systematic review and meta-analysis to examine the efficacy and safety of macrolide therapy for adult asthma. We searched randomized controlled trials from MEDLINE via the PubMed, CENTRAL, and Ichushi Web databases. The primary outcome was asthma exacerbation. The secondary outcomes were serious adverse events (including mortality), asthma-related quality of life (symptom scales, Asthma Control Questionnaire, and Asthma Quality of Life Questionnaire), rescue medication (puffs/day), respiratory function (morning peak expiratory flow, evening peak flow, and forced expiratory volume in 1 s), bronchial hyperresponsiveness, and minimum oral corticosteroid dose. Of the 805 studies, we selected seven studies for the meta-analysis, which was conducted using a random-effects model. University Hospital Medical Information Network Clinical Trials Registry (UMIN000050824). No significant difference between macrolide and placebo for asthma exacerbations was observed (risk ratio 0.71, 95 % confidence interval [CI] 0.46-1.09; p = 0.12). Macrolide therapy for adult asthma showed a significant improvement in rescue medication with short-acting beta-agonists (mean difference -0.41, 95 % CI -0.78 to -0.04; p = 0.03). Macrolide therapy did not show more serious adverse events (odd ratio 0.61, 95 % CI 0.34-1.10; p = 0.10) than those with placebo. The other secondary outcomes were not significantly different between the macrolide and placebo groups. Macrolide therapy for adult asthma may be more effective than placebo and could be a treatment option.